Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.comAbout Imricor Medical Systems Imricor Medical Systems, Inc. is a privately held medical technology company specializing in the magnetic resonance (MR) compatibility of devices. The company is developing a number of products to be commercialized for use during MR guided cardiac ablation procedures. The company is also actively licensing its technology to enable other medical devices to be MR compatible. Additional information on Imricor is available at www.imricor.com Safe harbor statement This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning development of MRI-compatible leads for use with the VNS Therapy® System using technology licensed from Imricor Medical Systems, Inc. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS therapy and sales of our products; reimbursement approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third parties; intellectual property protection and potential patent infringement claims; potential litigation relating to compliance with laws and regulations pertaining to our business; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the potential identification of material weaknesses in our internal controls over financial reporting; and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC). For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 29, 2011, and our Quarterly Reports on Form 10-Q for the fiscal quarters ended July 29, 2011, October 28, 2011 and January 27, 2012. Contact Information Greg Browne, CFOCyberonics, Inc.100 Cyberonics Blvd. Houston, TX 77058Main: (281) 228-7262Fax: (281) 218-9332 firstname.lastname@example.org Steve Wedan, CEOImricor Medical Systems, Inc.400 Gateway Blvd. Burnsville, MN 55337Main: (952) 818-8400Fax: (952) 818-8401 email@example.com SOURCE Cyberonics, Inc.